ABSTRACT: Despite significant advances in chemoimmunotherapy, chronic lymphocytic leukemia (CLL) is still incurable. This has prompted the development of new drugs and therapeutic strategies that include reactivating the impaired apoptosis (programed cell death). Several approaches to target apoptosis-regulating proteins have attracted attention. Among them, the approach to inhibit the activity of prosurvival members of the BCL-2 family with small-molecule BH3 mimetics (navitoclax, ABT-199) has proved to be most promising in clinical trials with CLL patients. Recently, the first BH3 mimetics targeting selectively the particular prosurvival protein MCL-1 (whose overexpression is involved in therapeutic resistance) have been identified. Furthermore, small molecules capable of directly activating proapoptotic proteins of the BCL-2 family have been characterized, indicating that novel BH3-mimetic drugs displaying this property may be designed. These discoveries are opening a new era in the development of BH3 mimetics for improving CLL therapy.
Introduction
The development of chemoimmunotherapy protocols combining purine analogs, alkylating agents, and monoclonal antibodies has led to clear improvements in treating patients with chronic lymphocytic leukemia (CLL). The FCR (fludarabine, cyclophosphamide, and rituximab) regimen or allied agents has enabled significant increases in the rate and duration of complete remissions and a prolongation of overall survival. 1 In spite of these advances, CLL remains incurable without allogenic transplantation. Novel therapeutic strategies are therefore needed to improve the treatments of patients. New monoclonal antibodies (eg, ofatumumab, obinutuzumab) and chemotherapeutics such as bendamustine are currently in clinical evaluation. 2, 3 Furthermore, several signals involved in the activation of the B-cell receptor and other signaling pathways such as the phosphatidylinositol-3 kinase (PI3K) are constitutively activated in CLL. Strategies to inhibit these signals are being developed especially with ibrutinib (an inhibitor of the Bruton's tyrosine kinase) and idelalisib (an inhibitor of the PI3K isoform). Both agents have proved promising in clinical trials in CLL and have been approved by the U.S. Food and Drug Administration. [2] [3] [4] Another attractive strategy is to target proteins that control apoptosis (programed cell death). Actually, CLL is thought to result from an imbalance between proliferation and apoptosis. Moreover, many prosurvival factors are overexpressed in CLL cells such as proteins of the BCL-2 and IAP families. 5 The BCL-2 family proteins regulate the mitochondrial outer membrane permeabilization (MOMP) responsible for the activation of caspases (proteolytic enzymes that are the executioners of the apoptotic program). Proteins of the IAP family (inhibitor of apoptosis protein) are caspase antagonists. Attempts to directly inhibit the expression of IAP proteins and prosurvival members of the BCL-2 family with specific antisense oligonucleotides did not provide convincing results in clinical trials. 6 The indirect and non-specific transcriptional inhibition of both families of proteins with cyclin-dependent inhibitors appeared somewhat disappointing. 6 No therapeutic benefit was recorded with the approach of inhibiting IAP activities using agents designed to mimic the endogenous IAP antagonist SMAC (second mitochondria-derived activator of caspases). 6 By contrast, significant therapeutic effects were observed with BH3 mimetics, which can antagonize the activity of prosurvival BCL-2 family proteins. 6 The aim of the present article is to highlight the great potential of these agents and the latest developments in BH3-mimetic research, which undoubtedly constitute a new avenue in improving CLL therapy.
BCL-2 Family Proteins
Proteins of the BCL-2 family 7 are characterized by their domains of homology to BCL-2 (BH1-BH4) and their functional activities. This family includes prosurvival members (BCL-2, BCL-XL, BCL-W, MCL-1, A1) and proapoptotic members (Fig. 1) . The latter comprise the MOMP effectors BAX and BAK and the BH3-only members (so-called because they have only the BH3 domain) such as BIM, PUMA, BID, BAD, and NOXA. The activity of the prosurvival members is to bind and sequester their proapoptotic counterparts, in particular BAX and BAK, which are thus inactive. All prosurvivals can bind to BAX, whereas only BCL-XL and MCL-1 can bind to BAK. The activity of BH3-only members is to antagonize the prosurvival proteins: by inserting their BH3 domain into the binding groove of prosurvival proteins, they inhibit the activity of the latter, which results in the release and conformational activation of BAX and BAK. Whereas BIM, PUMA, and BID can antagonize all prosurvival proteins, BAD inhibits only BCL-2, BCL-XL, and BCL-W and NOXA inhibits only MCL-1 and A1. Some BH3-only proteins (BIM, BID, PUMA) can directly activate BAX and BAK. Therefore, the specific interactions between the BCL-2 family proteins govern the balance between cell death and survival. 
BH3 Mimetics
This biological context has spawned the concept of the BH3 mimetic: a small molecule capable of mimicking the BH3 domain of BH3-only proteins should be able to bind to prosurvival proteins with high affinity and inhibit their activity, leading to BAX/BAK activation and thus to caspase activation and apoptosis. 7 The BH3-mimetic concept has prompted the design of numerous small BH3 peptides or organic molecules. 8, 9 However, many of the generated compounds turned out to act through off-target mechanisms. Only a few of them were found to behave as authentic BH3 mimetics with the ability to bind prosurvival proteins with high affinity and to induce BAX/BAK-dependent apoptosis in malignant cells. 8, 9 The prototype ABT-737 and its orally bioavailable derivative navitoclax (formerly, ABT-263) bind and antagonize BCL-2, BCL-XL, and BCL-W (so they are referred to as BAD-like BH3 mimetics). 10, 11 Navitoclax has shown significant therapeutic activity in cancer patients but with a doselimiting thrombocytopenia because of inhibition of BCL-XL (that is a prosurvival factor for platelets). 12 To avoid this toxic side-effect, the ABT-199 derivative, which is specific for BCL-2 and does not bind to BCL-XL, was then designed. 13 The first clinical trials with ABT-199 have yielded impressive results without thrombocytopenia. 13, 14 Preclinical studies have recently enabled to characterize other bona fide BH3 mimetics such as BM-1197 (a BAD-like inhibitor as navitoclax), A-1155463 (specific for BCL-XL), and BIM SAHB (a stapled peptide derived from the BH3 domain of BIM and targeting a broad range of prosurvival apoptotic signals increase the expression of Bh3-only proteins that antagonize their prosurvival partners, leading to the release and activation of the momp effectors BaX and Bak. the latter can also be directly activated by some Bh3-only proteins. B: these interactions are selective-the Bh3-only protein Bad is able to bind only to BCL-2, BCL-XL, and BCL-W and noXa can bind only to mCL-1 and a1, whereas Bim, Bid, and puma can bind to all prosurvival proteins. the latter can interact with BaX, whereas only BCL-XL, mCL-1, and possibly a1 can interact with Bak.
BCL-2 proteins).
15-17 Several MCL-1-selective inhibitors were identified (eg, MIM-1, small-molecule Mcl-1 inhibitor, TW-37), but none of them fully meet the main criteria that define an authentic BH3 mimetic.
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BCL-2 Family Proteins in CLL
Most prosurvival members of the BCL-2 family are overexpressed in CLL cells. 23, 24 The upregulated BCL-2 protein and the expression ratio relative to its proapoptotic ligand BAX are undoubtedly involved in the survival advantage of the leukemic cells. The BCL-2 overexpression results from losses of micro-interfering RNAs miR-15a and miR-16 in some cases. 25 The unique prosurvival protein MCL-1, which is known to play a crucial role in malignant development and resistance to chemotherapy in many cancers, 26 is also upregulated in CLL cells. High MCL-1 levels were inversely correlated with in vitro and in vivo responses to fludarabine. 27 They were found to be correlated with prognostic markers (disease stage, mutation status, ZAP-70 positivity, and CD38 expression) and to be predictive of patients' clinical outcome. 28, 29 High MCL-1 levels have also been observed in CLL lymph node cells, which are thought to be involved in patients' drug resistance and relapse. 30 In addition, MCL-1 silencing has been shown to result in apoptosis induction in CLL cells in vitro. 31 Lastly, convergent data have highlighted that the MCL-1/ NOXA axis represents an attractive target for CLL therapy.
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BH3 Mimetics in CLL Therapy
Navitoclax. After the first published phase I study of navitoclax in non-Hodgkin's lymphoma, which had shown 22% partial responses (PRs), 33 Roberts et al reported encouraging data of a phase I trial in patients with relapsed or refractory CLL: 35% of PRs were recorded, albeit without complete responses (CRs) and with 18% of grade 4 thrombocytopenia.
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ABT-199. An initial observation had indicated a reduction in tumor burden in the first three CLL patients recruited into a clinical trial of ABT-199. 13 These promising data were followed by a preliminary report of a phase I study of ABT-199 in high-risk relapsed/refractory CLL showing 23% of CR and 84% of overall responses.
14 This has been further confirmed by the latest results 35 : 22% of the 84 patients recruited for two years have shown CR with no evidence of cancer in five of nine evaluated patients, 57% have achieved PR; and the objective response rate was 79% with a median duration of response of 20.5 months. Overall, 59% of the patients have survived for two years without leukemia progression. Interestingly, the CR rate was similar in high-risk patients, including those having p53 deficiency because of the deletion in chromosome 17. 35 Although the occurrence of tumor lysis syndrome has slowed clinical development, phase III trials combining ABT-199 with chemoimmunotherapy are now ongoing.
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Discovery of Novel BH3 Mimetics
The latest developments in BH3-mimetic research have revealed several novel types of small molecules targeting BCL-2 family proteins that are of potential interest for CLL therapy. These compounds are described below (recapitulated in Table 1 , which includes the comparison with previous authentic and putative BH3 mimetics).
First MCL-1-selective BH3 mimetics. Because the survival of malignant cells depends at least partly on MCL-1 in many cancers, including CLL, efforts focused on the identification of small molecules targeting selectively MCL-1. Despite the difficulties of this challenge, a series of MCL-1 inhibitors derived from indole-2-carboxilic acid has been obtained by high-throughput screening and structure-guided design. 37 The compounds bind to MCL-1 with excellent high affinity (0.45 nM) and selectivity over other prosurvival BCL-2 family proteins. A mechanistic study has shown that the lead compound A-1210477 and related analogs can disrupt the interactions of MCL-1 with BIM and NOXA, penetrate living cells, and act via an on-target mechanism. BaX activator putative puma-Bh3 peptide 42, 43 Bak activator putative puma sahB analog 44 BaX activator and BCL-2/mCL-1 inhibitor putative
Note: *subject of controversy.
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Abbreviations: pr, partial responses; Cr, complete responses.
They induce the main hallmarks of the caspase-dependent mitochondrial apoptosis (including BAX/BAK activation) in multiple myeloma and non-small cell lung cancer cell lines that have been validated to be MCL-1 dependent. These compounds are therefore the first BH3 mimetics targeting selectively MCL-1. Lastly, the fact that A-1210477 synergizes with navitoclax to trigger apoptosis is of interest given that MCL-1 is a key factor in the resistance of malignant cells to ABT-737 and navitoclax.
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Small-molecule direct activators of BAX and BAK. The BH3-mimetic concept has recently been used to generate small molecules that can directly activate the MOMP effectors BAX and BAK. The first example was provided by Walensky and colleagues who had characterized a stapled peptide (BIM SAHB) derived from the BIM BH3 domain that is capable of binding BAX at a site that directly triggers its activation. 40 By computational screening of small molecules displacing BIM SAHB from BAX, they have further identified the substituted pirazolone molecule BAM-7, which can engage BAX and trigger its activation and subsequent apoptosis. 41 Although its binding affinity has not been determined, BAM-7 might be used to design BH3 mimetics capable of directly activating BAX. Moreover, a short peptide modeled on the PUMA BH3 domain has been reported to bind BAK with high affinity and to induce its activation and apoptosis as well. 42, 43 The identification of these two small molecules therefore indicates that it is possible to obtain BH3 mimetics having the ability to directly activate proapoptotic proteins of the BCL-2 family.
Dual proapoptotic activator and prosurvival inhibitor. The BH3-mimetic strategy has lastly allowed the discovery of a small molecule with particular properties. 44 A stapled peptide derived from the PUMA BH3 region (called PUMA SAHB) has been found to not only bind and inhibit BCL-2 and MCL-1 but also directly bind and activate BAX. A cell permeable analog of PUMA SAHB (and exhibiting the same properties) has been shown to elicit mitochondrial apoptosis in neuroblastoma cells. 44 These data suggest for the first time the possibility to design a BH3 mimetic possessing the dual property of proapoptotic activator and prosurvival inhibitor.
Conclusions and Perspectives
Targeted therapy is one of the current modalities to improve cancer treatments. Targeting apoptosis appeared as a new paradigm to assist chemoimmunotherapy particularly in CLL, a disease characterized by apoptosis deficiency. Unlike some disappointing apoptosis-based approaches, the strategy to inhibit the activity of prosurvival BCL-2 family proteins with selective BH3 mimetics is hopeful. These small molecules display the advantage to be highly specific for their target, and the clinical results observed with ABT-199 as a single agent in CLL are impressive. However, this drug is specific for BCL-2 and does not antagonize MCL-1. The latter is a unique, crucial prosurvival protein, and its overexpression is frequently involved in therapeutic resistance. It is also a cause of resistance of CLL cells to navitoclax and ABT-199 in vitro. The recent discovery of A-1210477 and its related analogs, which are the first authentic BH3 mimetics targeting selectively MCL-1, are therefore a great step forward in both BH3-mimetic research and treating CLL patients. Such MCL-1 inhibitors could induce less toxic side-effects in patients than the complete loss of MCL-1 by drugs that inhibit protein expression (such as CDK inhibitors). 45 Also of considerable interest is the identification of several small molecules derived from BH3 peptides, which are capable of directly activating the proapoptotic proteins BAX and BAK. The latter are indeed the effectors of the MOMP that is responsible for caspase activation. The discovery of these direct activators is not surprising because it is known that some BH3-only proteins can directly activate BAX and BAK (without needing the inhibition of their prosurvival ligands). 7 The clinical use of such direct activators should display reduced toxicities as compared to many inhibitors. A striking discovery is the characterization of the BH3 peptide analog that can both activate BAX and inhibit BCL-2 and MCL-1. Together, these novel types of small molecules provide proof of concept that BH3 mimetics, having the property to activate proapoptotic BCL-2 proteins or the dual property of proapoptotic activator and prosurvival inhibitor, may be designed.
Much efforts are still necessary in order to implement the clinical use of MCL-1-specific and direct-activator BH3 mimetics. Nevertheless, a new era is coming up with the latest developments in the field of BH3-mimetic research that should benefit to CLL therapy.
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